MX346335B - Composiciones antisentido, y metodos para obtener y usar las mismas. - Google Patents

Composiciones antisentido, y metodos para obtener y usar las mismas.

Info

Publication number
MX346335B
MX346335B MX2015003911A MX2015003911A MX346335B MX 346335 B MX346335 B MX 346335B MX 2015003911 A MX2015003911 A MX 2015003911A MX 2015003911 A MX2015003911 A MX 2015003911A MX 346335 B MX346335 B MX 346335B
Authority
MX
Mexico
Prior art keywords
making
methods
same
antisense compositions
pharmaceutical formulations
Prior art date
Application number
MX2015003911A
Other languages
English (en)
Inventor
Francesca Viti
Sergio Baroni
Salvatore Bellinvia
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX346335B publication Critical patent/MX346335B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas para la administración oral de oligonucleótidos antisentido, tales como oligonucleótidos antisentido contra smad7; las formulaciones farmacéuticas pueden usarse para tratar enfermedad de Crohn, colitis ulcerativa y enfermedad inflamatoria crónica del intestino.
MX2015003911A 2008-11-13 2009-11-13 Composiciones antisentido, y metodos para obtener y usar las mismas. MX346335B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425727 2008-11-13
US15229709P 2009-02-13 2009-02-13
PCT/EP2009/008087 WO2010054826A1 (en) 2008-11-13 2009-11-13 Antisense compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
MX346335B true MX346335B (es) 2017-03-14

Family

ID=42101499

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011005042A MX2011005042A (es) 2008-11-13 2009-11-13 Composiciones antisentido, y metodos para obtener y usar las mismas.
MX2015003911A MX346335B (es) 2008-11-13 2009-11-13 Composiciones antisentido, y metodos para obtener y usar las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011005042A MX2011005042A (es) 2008-11-13 2009-11-13 Composiciones antisentido, y metodos para obtener y usar las mismas.

Country Status (21)

Country Link
US (7) US8912154B2 (es)
EP (2) EP2364360B1 (es)
JP (7) JP5719776B2 (es)
KR (2) KR101921014B1 (es)
CN (2) CN107007616A (es)
AU (4) AU2009315898B2 (es)
CA (2) CA2743329C (es)
CY (1) CY1119140T1 (es)
DK (1) DK2364360T3 (es)
ES (1) ES2627745T3 (es)
HR (1) HRP20170926T1 (es)
HU (1) HUE032368T2 (es)
LT (1) LT2364360T (es)
MX (2) MX2011005042A (es)
NZ (1) NZ592673A (es)
PL (1) PL2364360T3 (es)
PT (1) PT2364360T (es)
RS (1) RS56049B1 (es)
RU (2) RU2593939C2 (es)
SI (1) SI2364360T1 (es)
WO (1) WO2010054826A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
LT2364360T (lt) 2008-11-13 2017-08-10 Nogra Pharma Limited Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai
RU2678450C2 (ru) 2011-09-15 2019-01-29 Ногра Фарма Лимитед Способы контроля восприимчивости анти-smad7 терапии
ITCO20120008A1 (it) * 2012-03-01 2013-09-02 Nuovo Pignone Srl Metodo e sistema per monitorare la condizione di un gruppo di impianti
CN104487574B (zh) * 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US20140122184A1 (en) * 2012-10-29 2014-05-01 Elwha Llc Food Supply Chain Automation Grocery Information System And Method
US20150335763A1 (en) * 2013-01-09 2015-11-26 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof
CA2903597C (en) * 2013-03-15 2023-04-04 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
JP2017515896A (ja) * 2014-05-09 2017-06-15 ノグラ ファーマ リミテッド 炎症性腸疾患の処置の方法
EP3207135A2 (en) * 2014-10-17 2017-08-23 Celgene Alpine Investment Company II, LLC Isotopologues of smad7 antisense oligonucleotides
JP2017537973A (ja) * 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP6583954B2 (ja) * 2015-01-08 2019-10-02 日東電工株式会社 展示装置および映像展示方法
WO2016130832A1 (en) * 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
EP3355896A2 (en) * 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
MA44309A (fr) 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
US20190046490A1 (en) 2016-02-26 2019-02-14 Nogra Pharma Limited Methods of treating lactose intolerance
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
EP3562943A1 (en) 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
WO2020152350A1 (en) 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
CN113748207A (zh) 2019-02-26 2021-12-03 诺格拉制药有限公司 脆性x智力低下蛋白干扰寡核苷酸及其使用方法
WO2021094616A1 (en) 2019-11-15 2021-05-20 Nogra Pharma Limited Il-34 antisense agents and methods of using same
WO2022243299A1 (en) 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
ES2220915T3 (es) 1993-09-24 2004-12-16 Advanced Immuni T, Inc. Peptidos lineales y ciclicos para el tratamiento o prevencion de la enfermedad de crohn y/o colitis ulcerosa.
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998049348A1 (en) 1997-04-30 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced bioavailability
IE970794A1 (en) 1997-09-24 2000-08-23 Elan Corp Plc Composition and method for enhancing paracellular transport across cell layers
US7341741B1 (en) * 1997-09-26 2008-03-11 Jean-Pierre Sachetto Pharmaceutical composition for the treatment of inflammatory bowel disease
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1469009A2 (en) 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7700572B2 (en) 2001-11-02 2010-04-20 Giuliani International, Ltd. SMAD7 inhibitors for the treatment of CNS diseases
ZA200502318B (en) * 2002-10-16 2006-11-29 Takeda Pharmaceutical Controlled release preparation
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
AU2004259006B2 (en) * 2003-07-24 2010-10-07 Glaxosmithkline Llc Orally dissolving films
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
ATE468846T1 (de) 2004-03-26 2010-06-15 Lek Pharmaceuticals Magenresistente pharmazeutische dosierform mit n- (2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d- glutaminsäure (lk-423)
CA2528191A1 (en) 2004-11-26 2006-05-26 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
CN101151035A (zh) * 2004-12-02 2008-03-26 Isis制药公司 用于治疗炎性肠病的治疗性反义寡核苷酸组合物
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
WO2007016350A2 (en) 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007047553A2 (en) 2005-10-14 2007-04-26 Zweig Jack I Methods and compositions for treatment of prostate intraepithelial neoplasia
CN1850135A (zh) * 2006-03-09 2006-10-25 陈世忠 一种鸦胆子油肠溶软胶囊制剂及其制备方法和其应用
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
LT2364360T (lt) 2008-11-13 2017-08-10 Nogra Pharma Limited Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai
WO2011048125A1 (en) * 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
RU2678450C2 (ru) 2011-09-15 2019-01-29 Ногра Фарма Лимитед Способы контроля восприимчивости анти-smad7 терапии
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
CA2903597C (en) 2013-03-15 2023-04-04 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
JP2017515896A (ja) 2014-05-09 2017-06-15 ノグラ ファーマ リミテッド 炎症性腸疾患の処置の方法
CA2956683A1 (en) 2014-07-28 2016-02-04 Nogra Pharma Limited Methods and compositions for diagnosing and treating inflammatory bowel disorders
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
CA3014383A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
EP3562943A1 (en) 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
EP3121280A1 (en) 2017-01-25
US20190374472A1 (en) 2019-12-12
CN102216458B (zh) 2017-05-24
PL2364360T3 (pl) 2017-09-29
US10272047B2 (en) 2019-04-30
US20120015033A1 (en) 2012-01-19
AU2015246097B2 (en) 2018-01-18
CN107007616A (zh) 2017-08-04
CN102216458A (zh) 2011-10-12
JP6095744B2 (ja) 2017-03-15
US20170107520A1 (en) 2017-04-20
RS56049B1 (sr) 2017-09-29
CA2743329A1 (en) 2010-05-20
AU2009315898B2 (en) 2015-07-23
JP2014196356A (ja) 2014-10-16
RU2739302C2 (ru) 2020-12-22
NZ592673A (en) 2013-01-25
RU2011123876A (ru) 2012-12-20
KR101767145B1 (ko) 2017-08-11
DK2364360T3 (en) 2017-06-19
AU2020202813A1 (en) 2020-05-21
AU2009315898A1 (en) 2010-05-20
JP2023138750A (ja) 2023-10-02
RU2016127232A3 (es) 2019-12-18
CY1119140T1 (el) 2018-02-14
JP2017075184A (ja) 2017-04-20
CA3085272A1 (en) 2010-05-20
PT2364360T (pt) 2017-06-27
US20210290656A1 (en) 2021-09-23
US8912154B2 (en) 2014-12-16
RU2593939C2 (ru) 2016-08-10
JP2015232039A (ja) 2015-12-24
JP5719776B2 (ja) 2015-05-20
LT2364360T (lt) 2017-08-10
HUE032368T2 (en) 2017-09-28
JP6530772B2 (ja) 2019-06-12
AU2015246097A1 (en) 2015-11-12
US20160222383A1 (en) 2016-08-04
KR101921014B1 (ko) 2018-11-21
KR20170092719A (ko) 2017-08-11
US20150232854A1 (en) 2015-08-20
US9314434B2 (en) 2016-04-19
CA2743329C (en) 2020-09-01
ES2627745T3 (es) 2017-07-31
AU2017279624A1 (en) 2018-01-18
JP2012508705A (ja) 2012-04-12
US9499819B2 (en) 2016-11-22
SI2364360T1 (sl) 2017-08-31
RU2016127232A (ru) 2018-12-06
US9982264B2 (en) 2018-05-29
HRP20170926T1 (hr) 2017-09-22
US20150125523A1 (en) 2015-05-07
JP7377624B2 (ja) 2023-11-10
AU2017279624B2 (en) 2020-02-06
JP2019151658A (ja) 2019-09-12
EP2364360A1 (en) 2011-09-14
KR20110086599A (ko) 2011-07-28
MX2011005042A (es) 2011-08-17
WO2010054826A1 (en) 2010-05-20
JP2021138778A (ja) 2021-09-16
EP2364360B1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
TN2011000414A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof
MY158504A (en) Fatty acid niacin conjugates and their uses
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
IN2012DN01233A (es)
MX362382B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX348823B (es) Formulaciones estables de linaclotida.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX2009009153A (es) Pirano-pirazol-aminas.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
DE602007007934D1 (en) Imidazoazephinonverbindungen
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives
EP2373327A4 (en) COMPOSITION WITH EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN 1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
MY148611A (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
TN2011000018A1 (en) Pharmaceutical formulations containing dopamine receptor ligands